[go: up one dir, main page]

DK3291679T3 - Ændring af mikrobielle populationer og modificering af mikrobiota - Google Patents

Ændring af mikrobielle populationer og modificering af mikrobiota Download PDF

Info

Publication number
DK3291679T3
DK3291679T3 DK16719873.8T DK16719873T DK3291679T3 DK 3291679 T3 DK3291679 T3 DK 3291679T3 DK 16719873 T DK16719873 T DK 16719873T DK 3291679 T3 DK3291679 T3 DK 3291679T3
Authority
DK
Denmark
Prior art keywords
modification
microbiota
microbial populations
populations
microbial
Prior art date
Application number
DK16719873.8T
Other languages
English (en)
Inventor
Jasper Clube
Christian Grøndahl
Morten Sommer
Der Helm Eric Van
Ruben Vazquez-Uribe
Original Assignee
Snipr Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57217569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3291679(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1507773.8A external-priority patent/GB201507773D0/en
Priority claimed from GBGB1507776.1A external-priority patent/GB201507776D0/en
Priority claimed from GBGB1507775.3A external-priority patent/GB201507775D0/en
Priority claimed from GBGB1507774.6A external-priority patent/GB201507774D0/en
Priority claimed from GBGB1508461.9A external-priority patent/GB201508461D0/en
Priority claimed from GBGB1509366.9A external-priority patent/GB201509366D0/en
Priority claimed from GBGB1510891.3A external-priority patent/GB201510891D0/en
Priority claimed from GBGB1518402.1A external-priority patent/GB201518402D0/en
Priority claimed from GB1600417.8A external-priority patent/GB2531454A/en
Priority claimed from GBGB1600418.6A external-priority patent/GB201600418D0/en
Application filed by Snipr Tech Ltd filed Critical Snipr Tech Ltd
Publication of DK3291679T3 publication Critical patent/DK3291679T3/da
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/60—Isolated nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
DK16719873.8T 2015-05-06 2016-05-03 Ændring af mikrobielle populationer og modificering af mikrobiota DK3291679T3 (da)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB1507776.1A GB201507776D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (4)
GBGB1507775.3A GB201507775D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (3)
GBGB1507774.6A GB201507774D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (2)
GBGB1507773.8A GB201507773D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (1)
GBGB1508461.9A GB201508461D0 (en) 2015-05-17 2015-05-17 Products uses and methods (4.2)
GBGB1509366.9A GB201509366D0 (en) 2015-05-31 2015-05-31 Products, uses & methods (6)
GBGB1510891.3A GB201510891D0 (en) 2015-06-20 2015-06-20 Products, uses & methods (7)
GBGB1518402.1A GB201518402D0 (en) 2015-10-17 2015-10-17 Products, uses & methods (8)
GB1600417.8A GB2531454A (en) 2016-01-10 2016-01-10 Recombinogenic nucleic acid strands in situ
GBGB1600418.6A GB201600418D0 (en) 2016-01-10 2016-01-10 Products, uses & methods (1.2)
PCT/EP2016/059803 WO2016177682A1 (en) 2015-05-06 2016-05-03 Altering microbial populations & modifying microbiota

Publications (1)

Publication Number Publication Date
DK3291679T3 true DK3291679T3 (da) 2022-01-17

Family

ID=57217569

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16719873.8T DK3291679T3 (da) 2015-05-06 2016-05-03 Ændring af mikrobielle populationer og modificering af mikrobiota

Country Status (18)

Country Link
US (27) US9701964B2 (da)
EP (10) EP3907285A1 (da)
JP (4) JP2018515138A (da)
KR (3) KR20200091499A (da)
CN (2) CN107667173A (da)
AU (5) AU2016257306B2 (da)
CA (1) CA2984975A1 (da)
DE (1) DE112016002056T5 (da)
DK (1) DK3291679T3 (da)
ES (1) ES2905525T3 (da)
HK (1) HK1245016A1 (da)
IL (4) IL310108B1 (da)
NZ (1) NZ738068A (da)
PL (1) PL3291679T3 (da)
RU (1) RU2017142352A (da)
SG (1) SG11201708706YA (da)
SI (1) SI3291679T1 (da)
WO (1) WO2016177682A1 (da)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
SG11201504523UA (en) 2012-12-12 2015-07-30 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US11135273B2 (en) 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
KR20240172759A (ko) 2013-06-17 2024-12-10 더 브로드 인스티튜트, 인코퍼레이티드 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲ­Ｃａｓ 시스템, 벡터 및 조성물의 전달 및 용도
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
EP3653229A1 (en) 2013-12-12 2020-05-20 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
BR112016013520A2 (pt) 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3633032A3 (en) 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
ES2905525T3 (es) 2015-05-06 2022-04-11 Snipr Tech Ltd Alteración de poblaciones microbianas y modificación de la microbiota
EP4039816A1 (en) * 2015-05-29 2022-08-10 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
CN107922918B (zh) 2015-06-15 2022-10-21 北卡罗来纳州立大学 用于有效递送核酸和基于rna的抗微生物剂的方法和组合物
KR102575342B1 (ko) 2015-06-18 2023-09-05 더 브로드 인스티튜트, 인코퍼레이티드 표적외 효과를 감소시키는 crispr 효소 돌연변이
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
JP7067793B2 (ja) 2015-10-23 2022-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基編集因子およびその使用
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
GB2568182A (en) 2016-08-03 2019-05-08 Harvard College Adenosine nucleobase editors and uses thereof
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11267738B2 (en) * 2017-04-24 2022-03-08 Microbe Detectives Llc Method of using microbial DNA sequencing in recovering renewable resources from wastewater and other waste streams
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020525049A (ja) * 2017-06-25 2020-08-27 エスエヌアイピーアール・テクノロジーズ・リミテッドＳｎｉｐｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 微生物集団の変更及び細菌叢の改変
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
CN118530920A (zh) * 2017-07-12 2024-08-23 布里格姆妇女医院 具有益生菌特性的活减毒霍乱疫苗
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
GB201712733D0 (en) * 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019055582A1 (en) * 2017-09-12 2019-03-21 Ubabiologix Corp. COMPOSITIONS AND METHODS FOR SANITATION OF WASTE WATER
EP3697906A1 (en) 2017-10-16 2020-08-26 The Broad Institute, Inc. Uses of adenosine base editors
CN111727251B (zh) 2017-11-21 2024-09-20 克里斯珀医疗股份公司 用于治疗常染色体显性色素性视网膜炎的材料和方法
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN109899053B (zh) * 2017-12-08 2022-02-01 中国石油天然气股份有限公司 钻井井场的确定方法、装置及计算机可读存储介质
CN109971778B (zh) * 2017-12-27 2022-11-18 北京蓝晶微生物科技有限公司 一种在盐单胞菌中快速基因编辑的载体组合及其应用
CN108410880B (zh) * 2018-01-26 2021-10-22 昆明理工大学 一种丹波黑大豆柠檬酸转运蛋白基因及其应用
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019246043B2 (en) 2018-03-25 2024-07-04 Snipr Biome Aps. Treating and preventing microbial infections
EP3788152A4 (en) * 2018-05-04 2022-03-09 Locus Biosciences, Inc. METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIA
CN108588050B (zh) * 2018-05-14 2021-06-25 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
WO2019227080A1 (en) * 2018-05-25 2019-11-28 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
CA3105867A1 (en) * 2018-07-11 2020-01-16 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaines S.E.C. Bacterial conjugative system and therapeutic uses thereof
CN109136128B (zh) * 2018-08-23 2021-07-16 国家海洋局第一海洋研究所 一种副球菌及其筛选方法和在合成银纳米颗粒中的应用
EP3870691A4 (en) 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University Recombinant type i crispr-cas system
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN111119818B (zh) * 2018-10-30 2022-04-12 中国石油化工股份有限公司 一种油藏内源功能微生物定向调控的方法
WO2020146888A1 (en) * 2019-01-11 2020-07-16 The Trustees Of Columbia University In The City Of New York Microbiome engineering through engineered mobile genetic elements
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
WO2020176624A1 (en) * 2019-02-26 2020-09-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Probiotics and probiotic compositions having modified carbohydrate metabolism
WO2020191248A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Method and compositions for editing nucleotide sequences
CN110499353B (zh) * 2019-08-09 2023-11-07 佛山市第四人民医院(佛山市结核病防治所) 一种用于结核耐药诊断的微生物标志物及其应用
GB201913045D0 (en) * 2019-09-10 2019-10-23 Univ Oxford Innovation Ltd Biofilm transformation
CN110596364B (zh) * 2019-09-12 2020-06-23 江南大学 一种前列腺特异性抗原检测的比率电化学传感器的构建方法及其应用
US20220387525A1 (en) * 2019-09-18 2022-12-08 Ancilia, Inc. Compositions and methods for microbiome modulation
KR20220051259A (ko) * 2019-09-30 2022-04-26 시그마-알드리치 컴퍼니., 엘엘씨 표적화된 뉴클레아제를 이용하여 미생물총 조성물의 변조
CN114981408A (zh) * 2019-11-06 2022-08-30 洛可斯生物科学公司 Crispr cas系统和溶原性模块
US20230001020A1 (en) * 2019-11-25 2023-01-05 Baylor College Of Medicine Selective expansion of gene-targeted cells
WO2021119594A1 (en) * 2019-12-13 2021-06-17 The Regents Of The University Of California Reducing antibiotic resistance in bacteria using pro-active genetics
DE102020101859A1 (de) * 2020-01-27 2021-07-29 Oxana Karpf Verfahren zur Reduktion der Population mindestens einer adipogenen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung
EP4121531A1 (en) * 2020-03-16 2023-01-25 Cornell University Compositions and methods comprising improved guide rnas
US20230147495A1 (en) * 2020-03-27 2023-05-11 Phuc Hong Vo Genome engineering using crispr rna-guided integrases
JP7504650B2 (ja) * 2020-04-16 2024-06-24 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
JP7488096B2 (ja) * 2020-04-16 2024-05-21 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
JP7527830B2 (ja) * 2020-04-16 2024-08-05 旭化成株式会社 セルロース繊維乾燥体の製造方法、及び樹脂複合体の製造方法
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20230181659A1 (en) * 2020-05-14 2023-06-15 Cz Biohub Sf, Llc Phage-mediated delivery of genes to gut microbiome
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
WO2021257604A1 (en) * 2020-06-16 2021-12-23 Dsm Ip Assets B.V. A composition for reducing the risk of urinary tract infection and vaginal infection in women
CN111849822A (zh) * 2020-07-28 2020-10-30 上海海洋大学 对抗菌素敏感的非o1/o139型霍乱弧菌菌株及应用
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome
CN113201531B (zh) * 2021-04-27 2023-06-27 隆平生物技术(海南)有限公司 转基因玉米事件lw2-1及其检测方法
US20240384279A1 (en) * 2021-08-01 2024-11-21 Snipr Biome Aps Microbiota engineering
JP2024529014A (ja) * 2021-08-02 2024-08-01 トロビックス バイオ リミテッド 細胞による薬物代謝を調節するためのシステム、方法及びその組成物
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
EP4392550A1 (en) 2022-06-29 2024-07-03 SNIPR Biome ApS. Targeting e coli cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024023820A1 (en) * 2022-07-25 2024-02-01 Trobix Bio Ltd Systems for modulating microbiome target cells, methods and compositions thereof
WO2024086532A1 (en) * 2022-10-17 2024-04-25 Locus Biosciences, Inc. Staphylococcus phage compositions and cocktails thereof
CN116042450B (zh) * 2022-11-03 2024-10-01 杭州秀川科技有限公司 一株高效降解苯胺类物质的陶厄氏菌及其应用
CN116058432B (zh) * 2023-03-02 2023-06-16 莱芜泰禾生化有限公司 一种柠檬酸菌丝渣微生物饲料添加剂及其制备方法和应用
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
WO2025046062A1 (en) 2023-08-31 2025-03-06 Snipr Biome Aps A novel type of crispr/cas system

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928A (en) * 1838-09-19 Eccentbic bbake eob abbesting the motion of bailboad-cabs
US3003323A (en) 1958-01-29 1961-10-10 Armco Steel Corp Composite pile connector
US4626504A (en) 1983-07-01 1986-12-02 Lubrizol Genetics, Inc. DNA transfer vector for gram-negative bacteria
SE8505027D0 (sv) 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE4208785A1 (de) 1992-03-19 1993-09-23 Degussa Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen
WO1995001994A1 (en) 1993-07-09 1995-01-19 Synergen, Inc. Recombinant ctla4 polypeptides and methods for making the same
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1212422E (pt) 1999-08-24 2007-04-30 Medarex Inc Anticorpos contra citla-4 humana e suas utilizações
CA2430500A1 (en) 2000-01-11 2001-07-19 Intralytix, Inc. Method and device for sanitation using bacteriophages
WO2003060066A2 (en) 2001-11-07 2003-07-24 Musc Foundation For Research Development Nucleic acid delivery and expression
CA2396611A1 (en) 2002-07-31 2004-01-31 Plant Bioscience Limited Materials and methods for generating genetic disruptions in bacterial cells
BRPI0412153B8 (pt) 2003-07-02 2021-05-25 Innate Pharma Sas anticorpo monoclonal e fragmento de ligação a antígeno do anticorpo monoclonal
RU2396981C2 (ru) 2003-07-24 2010-08-20 Иннейт Фарма Способы и композиции для повышения эффективности антител для лечебных целей с использованием соединений, потенциирующих nk-клетки
WO2005046579A2 (en) 2003-10-06 2005-05-26 Gangagen, Inc. Defined dose therapeutic phage
CA2562457A1 (en) 2004-04-07 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Reporter plasmid phage packaging system for detection of bacteria
PL2287195T3 (pl) 2004-07-01 2019-10-31 Novo Nordisk As Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii
EP2446897A1 (en) 2005-01-06 2012-05-02 Novo Nordisk A/S Anti-KIR combination treatments and methods
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2619833C (en) 2005-08-26 2017-05-09 Danisco A/S Use of crispr associated genes (cas)
JP5419067B2 (ja) 2005-10-14 2014-02-19 イナート・ファルマ・ソシエテ・アノニム 増殖性障害を処置するための組成物および方法
EP2468765B1 (en) 2006-03-03 2015-04-22 ONO Pharmaceutical Co., Ltd. Tetramer of extracellular domain of PD-L1
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
US20100172874A1 (en) * 2006-12-18 2010-07-08 The Washington University Gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2604278B1 (en) 2007-01-11 2017-04-12 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
US20110002889A1 (en) 2007-03-02 2011-01-06 Rodolphe Barrangou Cultures with Improved Phage Resistance
US20110143997A1 (en) 2007-03-30 2011-06-16 Dow Agrosciences Llc Phage receptor binding proteins for antibacterial therapy and other novel uses
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AU2009213738B2 (en) 2008-02-11 2015-01-22 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
JP5344895B2 (ja) * 2008-12-10 2013-11-20 矢崎総業株式会社 充電監視装置
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
US8241498B2 (en) 2009-03-28 2012-08-14 Phage Biocontrol Research, Llc Process for remediating biofouling in water systems with virulent bacteriophage
JP2010285425A (ja) 2009-05-12 2010-12-24 Fujifilm Corp 腸内細菌叢構成比率調整剤
SG177689A1 (en) 2009-07-31 2012-02-28 Organon Nv Fully human antibodies to btla
JP2013503205A (ja) 2009-08-31 2013-01-31 アンプリミューン， インコーポレイテッド 移植拒絶反応を阻害するための方法および組成物
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
RS61136B1 (sr) 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8252576B2 (en) 2010-08-11 2012-08-28 Phage Biocontrol Research, Llc Use of prokaryote viruses to remediate bio-fouling
EP2630156B1 (en) * 2010-10-20 2018-08-22 DuPont Nutrition Biosciences ApS Lactococcus crispr-cas sequences
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
CA2837184C (en) 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
US20140113376A1 (en) 2011-06-01 2014-04-24 Rotem Sorek Compositions and methods for downregulating prokaryotic genes
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
WO2013025119A1 (ru) 2011-08-18 2013-02-21 Roschin Evgeniy Mikhailovich Способ определения расположения протетической верхней плоскости у пациентов
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
MX379517B (es) 2011-10-28 2025-03-10 Regeneron Pharmaceuticals Inc Ratones con receptor de linfocitos t modificados genéticamente.
ES2861435T3 (es) 2011-11-03 2021-10-06 Univ Pennsylvania Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CN110433230A (zh) 2012-04-30 2019-11-12 索那麦提科有限责任公司 霞多丽种子产品的治疗用途
EP2850102A1 (en) 2012-05-15 2015-03-25 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
LT2800811T (lt) 2012-05-25 2017-09-11 The Regents Of The University Of California Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10025647B2 (en) 2012-06-30 2018-07-17 Intel Corporation Memory poisoning with hints
JP2015523386A (ja) 2012-07-13 2015-08-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寛容を誘導するために正常ｂ細胞を枯渇させるためのｃａｒｔ１９の使用
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9460205B2 (en) * 2012-07-20 2016-10-04 Google Inc. Crowdsourced video collaboration
EP3808844A1 (en) 2012-07-25 2021-04-21 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
CN109793893B (zh) 2012-09-07 2023-05-26 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
ES2656619T3 (es) 2012-09-11 2018-02-27 Thylabisco Ab Composición prebiótica de tilacoides
CN104780763A (zh) 2012-09-13 2015-07-15 萨利克斯药品公司 给予利福昔明用于重量减轻和肥胖治疗的方法
US11060148B2 (en) 2012-10-16 2021-07-13 Dana-Farber Cancer Institute, Inc. Diagnosing and treating colorectal cancer
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
WO2014124226A1 (en) 2013-02-07 2014-08-14 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) * 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3620534B1 (en) 2013-03-14 2021-10-13 Caribou Biosciences, Inc. Crispr-cas compositions of nucleic acid-targeting nucleic acids
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
DK2981607T3 (da) 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
EP3017039B1 (en) 2013-07-01 2021-03-17 Massachusetts Institute of Technology Functionalization of endogenous bacteria
DE102013012448A1 (de) 2013-07-26 2015-01-29 Kuka Laboratories Gmbh Verfahren und Vorrichtung zum Bremsen einer Roboterachsanordnung
JP5729429B2 (ja) * 2013-07-29 2015-06-03 トヨタ自動車株式会社 接合構造、及び接合構造の製造方法
JP2016531907A (ja) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
EP3041498B1 (en) 2013-09-05 2022-02-16 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
US20150070747A1 (en) * 2013-09-09 2015-03-12 Qualcomm Mems Technologies, Inc. Display element reset using polarity reversal
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
TW201542816A (zh) 2013-09-18 2015-11-16 Kymab Ltd 方法、細胞與生物體
US20160237455A1 (en) * 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
SG11201602979RA (en) 2013-10-17 2016-05-30 Univ Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
WO2015069764A1 (en) 2013-11-05 2015-05-14 Temple University Of The Commonwealth System Of Higher Education Polycationic amphiphiles as antimicrobial agents
WO2015069682A2 (en) 2013-11-05 2015-05-14 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
DK3066201T3 (da) 2013-11-07 2018-06-06 Editas Medicine Inc Crispr-relaterede fremgangsmåder og sammensætninger med ledende grna'er
WO2015070193A1 (en) 2013-11-11 2015-05-14 Liu Oliver Compositions and methods for targeted gene disruption in prokaryotes
EP3375877A1 (en) 2013-11-18 2018-09-19 Crispr Therapeutics AG Crispr-cas system materials and methods
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US20150157670A1 (en) * 2013-12-06 2015-06-11 K&K Ventures, LLC Non-caloric probiotic composition and method of preparation
CN105980568B (zh) 2013-12-11 2019-12-03 瑞泽恩制药公司 用于靶向修饰基因组的方法和组合物
MX2016007327A (es) 2013-12-12 2017-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas.
BR112016013520A2 (pt) * 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
US10351452B2 (en) 2014-01-29 2019-07-16 Synphagen Llc Compositions for in vivo expression of therapeutic sequences in the microbiome
US10287590B2 (en) 2014-02-12 2019-05-14 Dna2.0, Inc. Methods for generating libraries with co-varying regions of polynuleotides for genome modification
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
WO2015148680A1 (en) * 2014-03-25 2015-10-01 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering
US11242525B2 (en) * 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
CN106170550A (zh) 2014-04-03 2016-11-30 麻省理工学院 用于产生导引rna的方法和组合物
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
HUE051354T2 (hu) * 2014-04-14 2021-03-01 Nemesis Bioscience Ltd Terapeutikum
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
WO2015189693A1 (en) 2014-06-12 2015-12-17 King Abdullah University Of Science And Technology Targeted viral-mediated plant genome editing using crispr/cas9
MX2017000419A (es) 2014-07-11 2017-08-16 Genentech Inc Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
EP3633032A3 (en) 2014-08-28 2020-07-29 North Carolina State University Novel cas9 proteins and guiding features for dna targeting and genome editing
US11274317B2 (en) 2014-09-05 2022-03-15 Vilnius University Targeted RNA knockdown and knockout by type III-A Csm complexes
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CA2966132A1 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
EP3224353B9 (en) 2014-11-26 2023-08-09 Technology Innovation Momentum Fund (Israel) Limited Partnership Targeted elimination of bacterial genes
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US20160244784A1 (en) 2015-02-15 2016-08-25 Massachusetts Institute Of Technology Population-Hastened Assembly Genetic Engineering
RU2017130462A (ru) 2015-03-02 2019-04-02 Синлоджик, Инк. Бактерия, созданная для лечения заболеваний, облегчаемых при уменьшении воспаления кишечника и/или укреплении мукозного барьера кишечника
ES2895725T3 (es) 2015-04-23 2022-02-22 Kaleido Biosciences Inc Compuestos terapéuticos de glicano y métodos de tratamiento
ES2905525T3 (es) 2015-05-06 2022-04-11 Snipr Tech Ltd Alteración de poblaciones microbianas y modificación de la microbiota
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
PL3294760T3 (pl) 2015-05-13 2021-11-08 Synlogic Operating Company, Inc. Zmodyfikowane bakterie do redukowania hiperfenyloalaninemii
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
EP4039816A1 (en) 2015-05-29 2022-08-10 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
EP3303401B1 (en) 2015-06-01 2024-10-16 The University of Chicago Treatment of cancer by manipulation of commensal microflora
CN107922918B (zh) 2015-06-15 2022-10-21 北卡罗来纳州立大学 用于有效递送核酸和基于rna的抗微生物剂的方法和组合物
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
EP3322797B1 (en) 2015-07-13 2023-11-29 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
KR20240137695A (ko) 2015-09-10 2024-09-20 위니베르시트카솔리끄드루뱅 암을 예방하기 위한 저온살균된 아커만시아의 용도
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
JP2018532412A (ja) 2015-10-30 2018-11-08 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
ME03003B (me) 2015-11-20 2018-10-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2017095440A1 (en) 2015-12-04 2017-06-08 Massachusetts Institute Of Technology Engineered phagemids
CA3006772A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
WO2017118985A1 (en) 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
US20190282628A1 (en) 2016-01-11 2019-09-19 Synlogic Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
US20190010506A1 (en) 2016-01-11 2019-01-10 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
EP3402497A1 (en) 2016-01-11 2018-11-21 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
US20170247690A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Oncoviral treatment with nuclease and chemotherapeutic
BR112018067538A2 (pt) 2016-03-03 2019-02-05 Univ Cornell inibidores de ire1-alfa de pequenas moléculas
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
WO2017189518A1 (en) 2016-04-25 2017-11-02 Yale University Bacteriophage compositions and uses thereof
AU2017261380A1 (en) 2016-05-06 2018-11-22 Editas Medicine, Inc. Genetically engineered cells and methods of making the same
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN110267651B (zh) 2016-09-27 2023-09-01 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018081502A1 (en) 2016-10-28 2018-05-03 Massachusetts Intitute Of Technology Synthetic bacteriophages and bacteriophage compositions
CA3048669A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
US11149269B2 (en) 2017-05-15 2021-10-19 New York University Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability
US20200215131A1 (en) 2017-05-24 2020-07-09 Viktor Veniaminovich Tets Methods for treating and preventing diseases
WO2018218231A1 (en) 2017-05-25 2018-11-29 The Broad Institute, Inc. Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
EP3630975A4 (en) 2017-05-26 2021-03-10 North Carolina State University RNA GUIDES MODIFIED TO MODULATE CAS9 ACTIVITY AND USAGE PROCEDURES
WO2018222969A1 (en) 2017-06-02 2018-12-06 Board Of Regents, The University Of Texas System Specific bacterial species and metabolite that improves immune checkpoint inhibitor therapy efficacy
EP3634473A4 (en) 2017-06-07 2021-03-24 The Rockefeller University ENHANCED CRISPR-TYPE GENE EDITING OR TARGET DESTRUCTION BY CO-EXPRESSION OF HETEROLOGICAL DNA REPAIR PROTEIN
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US10303379B2 (en) 2017-09-25 2019-05-28 International Business Machines Corporation Efficient adaptive read-ahead in log structured storage
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3788152A4 (en) 2018-05-04 2022-03-09 Locus Biosciences, Inc. METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIA
JP7426953B2 (ja) 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2020072254A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for killing target cells
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University Recombinant type i crispr-cas system
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
EP3894562A4 (en) 2018-12-11 2022-08-24 The University of Western Ontario CIS CONJUGATION PLASMIDIC SYSTEM
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
US20220403357A1 (en) 2019-11-12 2022-12-22 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
US20230235361A1 (en) 2020-07-03 2023-07-27 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses

Also Published As

Publication number Publication date
HK1245016A1 (zh) 2018-08-24
US20200085066A1 (en) 2020-03-19
US10624349B2 (en) 2020-04-21
PL3291679T3 (pl) 2022-04-25
EP3903586A1 (en) 2021-11-03
IL255427B (en) 2021-10-31
US20210283167A1 (en) 2021-09-16
JP2022106717A (ja) 2022-07-20
US10506812B2 (en) 2019-12-17
JP2020058369A (ja) 2020-04-16
EP3711488A1 (en) 2020-09-23
EP4005386A1 (en) 2022-06-01
US11147830B2 (en) 2021-10-19
AU2016257306A1 (en) 2018-01-04
US11400110B2 (en) 2022-08-02
KR20180002776A (ko) 2018-01-08
US11612617B2 (en) 2023-03-28
US20210386773A1 (en) 2021-12-16
IL293646B2 (en) 2024-07-01
NZ738068A (en) 2019-07-26
US20180084785A1 (en) 2018-03-29
EP3563684A1 (en) 2019-11-06
US11844760B2 (en) 2023-12-19
EP3907285A1 (en) 2021-11-10
US20200128832A1 (en) 2020-04-30
US10582712B2 (en) 2020-03-10
US12226430B2 (en) 2025-02-18
US20180146681A1 (en) 2018-05-31
AU2022202944A1 (en) 2022-05-26
US20240082289A1 (en) 2024-03-14
DE112016002056T5 (de) 2018-02-08
US9701964B2 (en) 2017-07-11
AU2016257306B2 (en) 2019-06-27
US11517582B2 (en) 2022-12-06
US20220233575A1 (en) 2022-07-28
IL293646B1 (en) 2024-03-01
EP3291679A1 (en) 2018-03-14
US11547716B2 (en) 2023-01-10
EP3461337A1 (en) 2019-04-03
IL283877A (en) 2021-07-29
EP4233546A2 (en) 2023-08-30
AU2019236694A1 (en) 2019-10-17
US11642363B2 (en) 2023-05-09
IL310108A (en) 2024-03-01
US20180084786A1 (en) 2018-03-29
KR20230174291A (ko) 2023-12-27
AU2019236694B2 (en) 2022-02-03
EP4169383A1 (en) 2023-04-26
WO2016177682A1 (en) 2016-11-10
US20160333348A1 (en) 2016-11-17
US20190133135A1 (en) 2019-05-09
US20170246221A1 (en) 2017-08-31
JP2024038120A (ja) 2024-03-19
US20210145006A1 (en) 2021-05-20
AU2024202021A1 (en) 2024-04-18
SI3291679T1 (sl) 2022-04-29
RU2019130337A3 (da) 2021-12-20
ES2905525T3 (es) 2022-04-11
IL293646A (en) 2022-08-01
CA2984975A1 (en) 2016-11-10
US20180064114A1 (en) 2018-03-08
EP3729967A1 (en) 2020-10-28
RU2017142352A (ru) 2019-06-06
IL283877B (en) 2022-07-01
RU2019130337A (ru) 2019-10-15
RU2017142352A3 (da) 2019-06-06
US20200077663A1 (en) 2020-03-12
CN114099712A (zh) 2022-03-01
US20200267992A1 (en) 2020-08-27
IL310108B1 (en) 2025-01-01
US20200205416A1 (en) 2020-07-02
US20220362280A1 (en) 2022-11-17
US20220273696A1 (en) 2022-09-01
AU2023202066B2 (en) 2024-04-18
IL255427A0 (en) 2017-12-31
US20190230936A1 (en) 2019-08-01
EP3291679B1 (en) 2021-12-15
US10524477B2 (en) 2020-01-07
US20200068901A1 (en) 2020-03-05
US10561148B2 (en) 2020-02-18
US20180064115A1 (en) 2018-03-08
US20210290654A1 (en) 2021-09-23
SG11201708706YA (en) 2017-11-29
US20170196225A1 (en) 2017-07-13
CN107667173A (zh) 2018-02-06
JP2018515138A (ja) 2018-06-14
US20180070594A1 (en) 2018-03-15
US20200337313A1 (en) 2020-10-29
KR20200091499A (ko) 2020-07-30
US20220241318A1 (en) 2022-08-04
AU2023202066A1 (en) 2023-05-11
KR102138209B1 (ko) 2020-07-28
EP4233546A3 (en) 2023-09-27
US10463049B2 (en) 2019-11-05
AU2022202944B2 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
DK3291679T3 (da) Ændring af mikrobielle populationer og modificering af mikrobiota
DK3872085T3 (da) Stam-virussekvenser og anvendelser heraf
DK3370770T3 (da) Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3170842T3 (da) Immunologisk effektorcelle af målrettet cld18a2, fremstillingsfremgangsmåde og anvendelse deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3319428T3 (da) Herbicid sammensætning omfattende cinmethylin og imazamox
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
KR20180084891A (ko) 구조 조성물 및 방법
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf